Nodal Staging in Patients with Locally Advanced Non-Small Cell Lung Cancer: Indications, Approaches, and Impact on Downstream Treatment Selection
Abstract
Locally advanced non-small cell lung cancer (NSCLC) is a biologically and clinically heterogeneous disease in which mediastinal lymph node involvement remains the principal prognostic and therapeutic discriminator. Accurate nodal staging guides selection among surgical resection, definitive chemoradiotherapy, immunotherapy, and targeted therapy. This narrative review synthesizes contemporary evidence on mediastinal staging modalities, nodal disease burden, and treatment selection in stage II-III NSCLC. Contemporary staging integrates CT and FDG-PET/CT with systematic tissue confirmation using EBUS-TBNA and EUS, with surgical mediastinal staging reserved for selected high-risk or discordant cases. The ninth edition TNM N2a/N2b distinction, increasing use of neoadjuvant and perioperative immunotherapy, and molecularly guided therapy have further amplified the clinical consequences of under- or over-staging. Nodal assessment should therefore be interpreted through a multidisciplinary framework that integrates anatomy, biology, treatment response, and patient operability.
Read the paper
Related studies
- Current state and future directions for deep learning based automatic seismic fault interpretation: A systematic review
- Physics of Partially Saturated Porous Media: Residual Saturation and Seismic-Wave Propagation
- Modern Imaging Using Seismic Reflection Data
- Effects of marine seismic surveys on free-ranging fauna: a systematic literature review
- A review of the recent seismic activity in the southern part of egypt (upper egypt)
- A review of research on mechanism of seismic attenuation and energy compensation
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.